Navigation Links
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure
Date:11/10/2008

SAN MATEO‚ Calif.‚ Nov. 10 /PRNewswire/ -- Corthera Inc. today announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure.

The interim Phase II results were presented by John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, in a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans. The data from the first 209 patients enrolled in the trial demonstrated beneficial trends in acute heart failure (AHF) signs, symptoms and outcomes with no evidence of renal toxicity. Relaxin appeared safe and well-tolerated over a wide dose range.

"The data indicate that relaxin is a very promising treatment for AHF," said Teerlink, co-principal investigator of the study. "Compared to placebo, relaxin's effect on the important endpoint of relieving dyspnea, breathlessness, was apparent within 6 hours after start of treatment. These initial effects lasted up to 14 days after treatment, something not previously seen with other therapies for AHF. Relaxin's safety profile in the study's patient population was benign during and following drug treatment, while blood pressure effects were predictable and manageable. There were also encouraging trends in other in-hospital endpoints, including weight-loss due to diuresis, incidence of worsening heart failure and length of hospital stay. The consistency of these improvements across multiple measures of outcomes is very encouraging."

Corthera's Pre-RELAX-AHF/RELAX-AHF study is a Phase II/III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, international trial designed to evaluate the efficacy and safety of relaxin for the treatment of AHF. In the Phase II Pre-RELAX-AHF study, the obje
'/>"/>

SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
2. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
3. Misonix Announces Interim Distribution Agreement for Italy
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
8. LPBP Inc. - Re-filing certification of interim filings
9. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
10. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Pathwork Diagnostics, a,genomics-based diagnostics company focused on oncology, ... has initiated an,investigational study of the Pathwork(TM) Tissue ... to help determine a tumor,s origin so that,tissue-specific ... of the first,institutions in the country to evaluate ...
... Sensor for Airborne Biological Threats Receives Government ... ... 6 ICx Technologies, a developer of,advanced technology solutions for ... its AirSentinel(R) ambient aerosol,sensors for detection of airborne biological threats. ...
... Exchange Symbol: RVX, ORLANDO, FL, Nov. ... pleased to announce today key scientific data,was ... novel features of,RVX-208, at the American Heart ... of Compound RVX-208 Increases,Serum Levels of ApoA-I ...
Cached Biology Technology:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4ICx Awarded Department of Defense Contract for AirSentinel Monitors 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 3
(Date:7/9/2014)... concern about the prevalence of antibiotic-resistant illness, Case ... pathway to disabling disease: blocking bacteria,s access to ... how bacterial siderophore, a small molecule, captures iron ... growth as well as how the body ... Their findings appear in a recent edition of ...
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Environmental and genetic factors influence a persons blood fat, ... disease (CAD). While there is some understanding of the ... defined. Now, in an international collaboration supported primarily by ... more than 25 genetic variants in 18 genes connected ...
... EVANSTON, Ill. --- Many researchers have tried to create a ... but most models have many different complicated factors, and no ... created a functional equation -- using only two parameters -- ... of Drosophila, better known as the fruit fly. They hope ...
... that facilitate the remarkably fast adaptation of intestinal bacteria ... issue of PLoS Genetics by researchers from INSERM and ... a simplified but ecologically relevant system the ... strain, Escherichia coli MG1655. E. coli is naturally resident ...
Cached Biology News:New genetic variants associated with lipid levels, risk for coronary artery disease 2New genetic variants associated with lipid levels, risk for coronary artery disease 3New genetic variants associated with lipid levels, risk for coronary artery disease 4New genetic variants associated with lipid levels, risk for coronary artery disease 5Researchers create mathematical model of fruit fly eyes 2Dissecting the genetic components of adaptation of E. coli to the mouse gut 2
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
Biology Products: